acute promyelocytic leukemia
acute promyelocytic leukemia
Explore linked clinical trials. Standard reference: MONDO:001288316 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Feasibility and Efficiency Study for the Implementation of a New Screening Method for Patients With Acute Myeloid Leukemia, in Laboratory Practice | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, acute promyelocytic leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Not yet recruiting | Not applicable | 2026-10-09 | NCT07867704 | |
| Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, acute myeloid leukemia, acute promyelocytic leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 3 | 2026-10-08 | NCT07504458 | |
| Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ... | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, Neoplasms, Nerve Tissue, Precursor Cell Lymphoblastic Leukemia-Lymphoma, acute myeloid leukemia, acute promyelocytic leukemia, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, myeloid leukemia, neoplasm, nerve sheath neoplasm, nervous system disorder, neurofibroma, neuromuscular disease, peripheral nervous system disorder, peripheral nervous system neoplasm, plexiform neurofibroma, sarcoma | Recruiting | Phase 1 | 2026-08-24 | NCT02390752 | |
| Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, acute promyelocytic leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Not applicable | 2026-08-06 | NCT03253848 | |
| Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, acute promyelocytic leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Not yet recruiting | Phase 2 / Phase 3 | 2026-06-30 | NCT07597941 | |
| Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, acute promyelocytic leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 2 | 2026-05-20 | NCT01409161 | |
| PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, acute promyelocytic leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 1 | 2026-04-17 | NCT02390635 | |
| Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL). | acute promyelocytic leukemia | Recruiting | Phase 3 | 2026-03-31 | NCT07503730 | |
| A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301) | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, acute promyelocytic leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Not yet recruiting | Phase 3 | 2025-12-29 | NCT07296445 | |
| Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, acute promyelocytic leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Not applicable | 2025-09-23 | NCT07187505 | |
| Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, acute promyelocytic leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 2 | 2025-05-30 | NCT06982274 | |
| Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia | acute promyelocytic leukemia | Recruiting | Phase 2 | 2025-02-18 | NCT05881265 | |
| Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, acute promyelocytic leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Enrolling by invitation | Phase 2 / Phase 3 | 2024-08-09 | NCT06544109 | |
| Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, acute promyelocytic leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 2 | 2024-04-15 | NCT04793919 | |
| RWE of 1st Line Treatment With ATO/ATRA for Adult APL | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, acute promyelocytic leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Not stated | 2024-01-09 | NCT04897490 | |
| Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, acute myeloid leukemia, acute promyelocytic leukemia, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, myeloid leukemia, neoplasm | Active, not recruiting | Not stated | 2023-08-31 | NCT00003861 |